Testing of chemicals

Lists of projects on the AOP development programme workplan

 

 

 

SECTION 1: Development of an adverse outcome pathway

Project 1.1: The Adverse Outcome Pathways for Skin Sensitisation Initiated by Covalent Binding to Proteins

Lead:

Inclusion in work plan:

Secretariat + consultant

2011

Project 1.2: The Adverse Outcome Pathways for Nonpolar Narcosis

Lead:

Inclusion in work plan:

United States

2012

 

Project 1.3: The Adverse Outcome Pathways for Acetylcholinesterase Inhibition

Lead:

Inclusion in work plan:

United States

2012

 

Draft AOP ready September 2013.

Project 1.4: Adverse Outcome Pathways for Five Cell Signalling Pathways Associated with Cell Proliferation and Differentiation that are Conserved Across Species

Lead:

Inclusion in work plan:

Secretariat + consultant

2010

 

Project 1.5: Two Adverse Outcome Pathways for Mitochondrial Toxicity

Lead:

Inclusion in work plan:

Secretariat + consultant

2011

 

Project 1.6: The Adverse Outcome Pathways for Embryonic Vascular Disruption and Developmental Defects

Lead:

Inclusion in work plan:

United States

2013

 

In progress, important milestones in 2013-2014.

Project 1.7: The Adverse Outcome Pathways for Sustained Activation of the Avian Aryl Hydrocarbon Receptor

Lead:

Inclusion in work plan:

Canada, BIAC

2013

 

Project 1.8: The Adverse Outcome Pathways for Mutagenic Modes of Action for Cancer

Lead:

Inclusion in work plan:

United States, BIAC

2014 (following re-submission)

 

Project 1.9: The Adverse Outcome Pathway on Upregulation of Thyroid Hormone Catabolism via Activation of Hepatic Nuclear Receptors, and Subsequent Adverse Neurodevelopmental Outcomes in Mammals

Lead:

Inclusion in work plan:

United States

2013

 

Draft AOP ready October 2013.

Project 1.10: The Adverse Outcome Pathway on Xenobiotic Induced Inhibition of Thyroperoxidase and Depressed Thyroid Hormone Synthesis and Subsequent Adverse Neurodevelopmental Outcomes in Mammals

Lead:

Inclusion in work plan:

United States

2013

 

Draft AOP ready October 2013.

Project 1.11: The Adverse Outcome Pathways for Heritable Germ Cell-Derived Disease (3 AOPs)

Lead:

Inclusion in work plan:

Canada

2013

 

AOP 1: Alkylation of DNA in male pre-meiotic germ cells causing inherited mutation; draft AOP ready in July 2013.

AOP 2: Chemical interaction with tubulin in oocytes leading to inherited aneuploidy; draft AOP ready in September 2013.

AOP 3: Stable bulky DNA adducts in male pre-meiotic germ cells causing point mutation leading to inherited DNA sequence mutation; draft AOP ready in January 2014.

Project 1.12: The Adverse Outcome Pathways linking Aromatase Inhibition, Androgen Receptor Agonism, Estrogen Receptor Antagonism, or Steroidogenesis Inhibition, to Impaired Reproduction in Small Repeat-Spawning Fish Species

Lead:

Inclusion in work plan:

United States

2013

 

Draft AOP submitted to OECD in April 2013.

Project 1.13: The Adverse Outcome Pathway on Neurotoxicant-induced Neuroinflammation: A Converging Key Event in an Adverse Outcome Pathway

Lead:

Inclusion in work plan:

Switzerland

Pending review by EAGMST

 

Project 1.14: The Adverse Outcome Pathways from Protein Alkylation to Liver Fibrosis

Lead:

Inclusion in work plan:

 

European Commission

2013

 

In progress, identification of partners.

Project 1.15: The Adverse Outcome Pathways for Neurotoxicity Induced by GABAA Receptor Inhibition

Lead:

Inclusion in work plan:

United States

2013

 

Draft AOP ready in September 2013.

Project 1.16: The Adverse Outcome Pathway Describing Hematotoxicity due to Nitroaromatics and N-hydroxyl anilines

Lead:

Inclusion in work plan:

United States

2013

 

Draft AOP ready in September 2013.

Project 1.17: The Adverse Outcome Pathway on CAR and PPARα-mediated Pathways to Non-genotoxic Rodent Liver Cancer

Lead:

Inclusion in work plan:

United States

2013

 

Draft AOP ready in February-April 2014.

Project 1.18: The Adverse Outcome Pathway on CAR and PXR-mediated Pathways to Rodent Liver Hyperplasia

Lead:

Inclusion in work plan:

United States

2013

 

Draft AOP ready in March 2014.

Project 1.19: The Adverse Outcome Pathway from Bile Salt Export Pump Inhibition to Cholestatic Liver Injury

Lead:

Inclusion in work plan:

Belgium

2013

 

Project 1.20: The Adverse Outcome Pathway for Sensitisation of the Respiratory Tract Induced by Covalent Binding to Proteins

Lead:

Inclusion in work plan:

ICAPO

2013

 

Project 1.21: Three Adverse Outcome Pathways from Peroxisome Proliferator-activated Receptors (PPARs) Activation Leading to Reproductive Toxicity in Rodents

Lead:

Inclusion in work plan:

European Commission

2014

 

Project 1.22: The Adverse Outcome Pathway from Binding of Antagonists to NMDAR during Brain Development (Synaptogenesis) Induces Impairment of Learning and Memory Abilities

Lead:

Inclusion in work plan:

European Commission

2014

Project 1.23: The Adverse Outcome Pathway from Binding of Agonists to NMDAR in Adult Brain Causes Excitotoxicity that Mediates Neuronal Cell Death, Contributing to Reduction of Cognitive Functions

Lead:

Inclusion in work plan:

European Commission

2014

Project 1.24: The Adverse Outcome Pathway from Cyp2E1 Stabilization by Substrate Binding Leading to Liver Cancer

Lead:

Inclusion in work plan:

Canada

2014

Project 1.25: The Adverse Outcome Pathway from Induction of Secretion of Inflammatory Cytokines Leading to Lung Emphysema

Lead:

Inclusion in work plan:

Canada

2014

 

SECTION 2: Development of an adverse outcome pathway case study

Project 2.1: The Adverse Outcome Pathways- Case Studies Using Aquatic Organism

Lead:

Inclusion in work plan:

United Kingdom and Japan

2013

 

Project 2.2: The Adverse Outcome Pathway on Hepatotoxicity due to 2,4,6-trinitrotoluene

Lead:

Inclusion in work plan:

United States

2013

 

Draft AOP ready in September 2013.

Project 2.3: The Adverse Outcome Pathway on Energy Metabolism by 2,6-Dinitroluene

Lead:

Inclusion in work plan:

United States

2013

 

Draft AOP ready in September 2013.

Project 2.4: The Adverse Outcome Pathway for Adipogenic Phenotype Mediated via Activation of PPARy

Lead:

Inclusion in work plan:

United States

2014

 

Project 2.5: Percellome Toxicogenomics Approach for AOP Binding: Case Study on Pentachlorophenol

Lead:

Inclusion in work plan:

Japan

2014

 

Project 2.6: Immunosuppression Initiated by Metal

Lead:

Inclusion in work plan:

Japan

2014

 

Project 2.7: A Non-mutagenic AOP for Nasal Tumours from Exposure to Weakly Genotoxic, Endogenous and Low Molecular Weight Substances: Vinyl Acetate, Acetaldehyde and Propylene Oxide

Lead:

Inclusion in work plan:

BIAC

2014

 

SECTION 3: Guidance documents related to adverse outcome pathway development including its evaluation

Project 3.1: Development of a Template for Recording Adverse Outcome Pathways (AOPs) and Associated Guidance Relating to How to Assess its Completeness

Lead:

Inclusion in work plan:

 

Secretariat

2011

 

Completed: Guidance and template published (No. 184 in OECD Series on Testing and Assessment)

Project 3.2: Glossary of the Terminology Associated with Adverse Outcome Pathways

Lead:

Inclusion in work plan:

Secretariat

2011

 

 

SECTION 4:  Knowledge management tool

Project 4.1: Web Based AOP Knowledge Management Tool

Lead:

Inclusion in work plan:

United States

2013

In development and beta-testing in 2013.

Project 4.2: Adverse Outcome Pathways Knowledge Base (AOP-KB)

Lead:

Inclusion in work plan:

European Commission, United States

2013

 

In progress.

 

SECTION 5: Others

Project 5.1: In vitro test method development strategy for the OECD Skin Sensitisation AOP

Lead:

Inclusion in work plan:

EC/ECVAM

2013

 

 

 

Countries list

  • Afghanistan
  • Albania
  • Algeria
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Brazil
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China (People’s Republic of)
  • Chinese Taipei
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Croatia
  • Cuba
  • Cyprus
  • Czech Republic
  • Côte d'Ivoire
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • Dominican Republic
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • European Union
  • Faeroe Islands
  • Fiji
  • Finland
  • Former Yugoslav Republic of Macedonia (FYROM)
  • France
  • French Guiana
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iraq
  • Ireland
  • Islamic Republic of Iran
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jersey
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kuwait
  • Kyrgyzstan
  • Lao People's Democratic Republic
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Libya
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macao (China)
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia (Federated States of)
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestinian Administered Areas
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Romania
  • Russian Federation
  • Rwanda
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Vincent and the Grenadines
  • Samoa
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Serbia and Montenegro (pre-June 2006)
  • Seychelles
  • Sierra Leone
  • Singapore
  • Slovak Republic
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Sudan
  • Spain
  • Sri Lanka
  • Sudan
  • Suriname
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • Tajikistan
  • Tanzania
  • Thailand
  • Timor-Leste
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Virgin Islands
  • Uruguay
  • Uzbekistan
  • Vanuatu
  • Venezuela
  • Vietnam
  • Virgin Islands (UK)
  • Wallis and Futuna Islands
  • Western Sahara
  • Yemen
  • Zambia
  • Zimbabwe
  • Topics list